Scientific ADVISORY BOARD

Dr. Baker is currently at Corus Pharma as Vice President Research. Prior to joining Corus, Dr. Baker was Chief Operating Officer and VP of Research for Optimer Pharmaceuticals, Inc., where he focused on developing novel therapeutics for infectious diseases and cancer. Previously, Dr. Baker served as Senior Vice President of Research and Preclinical Development for PathoGenesis Corporation. Prior to PathoGenesis, Dr. Baker was Associate Research Fellow at Abbott Laboratories, where he directed research in cardiovascular and anti-infective drug discovery. While at Abbott, his research efforts led to the discovery of a new class of antibiotics called "ketolides." Dr. Baker received his Ph.D. in Organic Chemistry from the University of Illinois, Champaign-Urbana and his BS degree in Chemistry from the University of Washington.

Dr. Hancock is a professor of Microbiology and Immunology at UBC and is a Canada Research Chair holder. He heads the UBC Centre for Microbial Diseases and Immunity Research and was the Founding Scientific Director of the Canadian Bacterial Diseases Network from 1989-96. He is a Founder of Inimex Pharmaceuticals Inc., and has served as a Scientific Advisory Board Member or consultant with 17 biotechnology and pharmaceutical companies. Dr. Hancock received his Ph.D. from Adelaide in 1974, did his postdoctoral work at Tübingen from 1975-77, at Berkeley from 1977-78. His research interests include antibiotic uptake and resistance, functional genomics and the development of small cationic peptides as novel antimicrobials and immune modulators. He has published more than 300 papers and reviews, and has 12 patents awarded.

Dr. Robin Cooper is the Senior Vice President of Pharmaceutical Sciences at Rigel Pharmaceuticals. Prior to joining Rigel, Dr. Cooper held various chemistry development research positions at Eli Lilly and Company. During his 32-year career at Eli Lilly and Company, Dr. Cooper was involved in bringing five compounds to the clinic. Dr. Cooper served on a number of discovery research/management groups, which evaluated Eli Lilly's research direction and strategic goals. From 1985-1997, Dr. Cooper also served as the discovery representative for various committees in support of external relationships and supported Lilly's corporate patent strategy. Since 1997, Dr. Cooper leveraged his extensive knowledge and expertise by founding Cooper Consulting Inc, which provides consulting services for large pharmaceutical and biotechnology companies, including Pfizer Inc, Procter & Gamble, Chiron Corporation and Vicuron. He is a member of the American Chemical Society, a fellow with the Chemical Society in London and a member of the editorial board of the Journal of Antibiotics. Dr. Cooper has also served as a journal reviewer for numerous peer-reviewed publications. Dr. Cooper holds a B.Sc. from Imperial College in London, England, a Ph.D. from Queen Mary College/Imperial College, followed by a year with Nobel Laureate Sir Derek Barton in London. He was awarded his D.Sc. by the University of London.

Dr. Zoe Diana Draelos, Clinical Associate Professor of Dermatology, Wake Forest University School of Medicine. Dr. Draelos is the author of the textbook Cosmetics in Dermatology, now in it second edition, and has contributed chapters on cosmetics in 23 textbooks, writing 260 published papers, and currently serving on five journal editorial boards. She is the editor of The Journal of Cosmetic Dermatology and founded Dermatology Consulting Services to provide education, perform adverse reaction evaluation, and conduct clinical studies in association with the industry.

Dr. Barbara Gilchrest, Professor and Chair, Department of Dermatology at Boston University School of Medicine and Chief of Dermatology at the Boston Medical Center (BMC). A Harvard Medical School graduate, Dr. Gilchrest is board certified in Internal Medicine and Dermatology. She is the author or editor of 11 books on skin aging, photoaging, and UV effects on skin and author of over 400 original articles, reviews, editorials, and invited textbook chapters. She is a section editor for the Journal of Investigative Dermatology, the leading research journal in the field, and serves on the editorial board of five other dermatology or aging journals. Her current research interests range from the molecular basis of skin aging to DNA damage responses in skin to clinical studies of photodynamic therapy for the prevention and treatment of photocarcinogenesis. Dr. Gilchrest is a member of the Institute of Medicine of the National Academies of Science.

Dr. Mark Lebwohl, Professor and Chairman, Department of Dermatology at Mount Sinai School of Medicine. Dr. Lebwohl is past president of the New York State Society of Dermatology and immediate past-chairman of the Psoriasis Task Force of the American Academy of Dermatology. He is also a member of the medical advisory board of the National Psoriasis Foundation and editor of Psoriasis Forum and Psoriasis Advance, the patient bulletin of the National Psoriasis Foundation. He is the “Medical Pearl” feature editor and as well as assistant editor of The Journal of the American Academy of Dermatology. Dr. Lebwohl has written several books on dermatology, authored or co-authored over 400 publications and is actively involved in clinical trials of new dermatologic treatments.